Camp4 Therapeutics Corp (NASDAQ: CAMP)

Sector: Healthcare Industry: Biotechnology CIK: 0001736730
Market Cap 170.21 Mn
P/B 2.90
P/E -3.19
P/S 44.77
ROIC (Qtr) -95.91
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 6.35 Mn
Debt/Equity (Qtr) 0.11

About

Price action

Investment thesis

Bull case

  • Healthy cash reserves of 76.88M provide 23.63x coverage of short-term debt 3.25M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 86.39M provides 13.61x coverage of total debt 6.35M, indicating robust asset backing and low credit risk.
  • Tangible assets of 86.39M provide robust 21.25x coverage of other current liabilities 4.07M, indicating strong asset backing.
  • Strong cash position of 76.88M provides 18.91x coverage of other current liabilities 4.07M, indicating excellent liquidity.
  • Cash reserves of 76.88M provide robust 9.73x coverage of current liabilities 7.90M, indicating strong short-term solvency.

Bear case

  • Investment activities of (506000) provide weak support for R&D spending of 39.84M, which is -0.01x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (47.13M) shows concerning coverage of stock compensation expenses of 3.64M, with a -12.93 ratio indicating potential earnings quality issues.
  • Free cash flow of (47.64M) provides weak coverage of capital expenditures of 506000, with a -94.15 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (53.40M) show weak coverage of depreciation charges of 3.59M, with a -14.87 ratio indicating high capital intensity and potential reinvestment needs.
  • Operating cash flow of (47.13M) barely covers operating expenses of 494000 with a -95.41 ratio, suggesting thin operational efficiency margins and limited flexibility.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,446.17 Bn -1,569.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 439.23 Bn 6,407.40 88.33 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 120.62 Bn 32.82 10.29 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 84.40 Bn 18.44 5.92 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 56.13 Bn 1,288.39 17.49 3.21 Bn
6 ARGX Argenx Se 47.89 Bn 31.79 24,973.95 -
7 BNTC Benitec Biopharma Inc. 42.45 Bn -1,015.00 0.00 0.00 Bn
8 INSM INSMED Inc 32.67 Bn -27.60 73.08 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 1.58 12.96
EV to Cash from Ops. EV/CFO -2.90 23.73
EV to Debt EV to Debt 21.55 772.65
EV to EBIT EV/EBIT -2.56 -11.30
EV to EBITDA EV/EBITDA -2.72 7.11
EV to Free Cash Flow [EV/FCF] EV/FCF -2.87 22.12
EV to Market Cap EV to Market Cap 0.80 68.89
EV to Revenue EV/Rev 35.97 199.70
Price to Book Value [P/B] P/B 2.90 22.62
Price to Earnings [P/E] P/E -3.19 -12.30
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.02
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.15
Interest Coverage Interest Coverage 0.00 857.11
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -20.19 -27.24
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 1,751.61 747.06
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -3.68 -48.21
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -2.26 -2.09
EBIT Growth (1y) % EBIT 1y % (Qtr) -3.68 -57.79
EBT Growth (1y) % EBT 1y % (Qtr) -3.68 -14.35
EPS Growth (1y) % EPS 1y % (Qtr) 159.54 -30.88
FCF Growth (1y) % FCF 1y % (Qtr) -2.50 -32.51
Gross Profit Growth (1y) % Gross Profit Growth (1y) % 0.00 227.96
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.04 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 9.73 3.79
Current Ratio Curr Ratio (Qtr) 9.83 7.23
Debt to Equity Ratio Debt/Equity (Qtr) 0.11 0.42
Interest Cover Ratio Interest Cover Ratio 0.00 857.11
Times Interest Earned Times Interest Earned 0.00 857.11
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -1,310.00 -18,509.94
EBIT Margin % EBIT Margin % (Qtr) -1,404.47 -18,862.18
EBT Margin % EBT Margin % (Qtr) -1,404.47 -19,783.19
Gross Margin % Gross Margin % (Qtr) 100.00 -8.62
Net Profit Margin % Net Margin % (Qtr) -1,404.50 -19,732.60